European Journal of Clinical Pharmacology

, Volume 64, Issue 4, pp 347–355 | Cite as

The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis

  • Jaroslav Chládek
  • Marie Simková
  • Jaroslava Vanecková
  • Milos Hroch
  • Jirina Chládkova
  • Jirina Martínková
  • Jaroslava Vávrová
  • Martin Beránek
Clinical Trial



We assessed the effect of folic acid (FA) on the pharmacokinetics and pharmacodynamics of low-dose oral methotrexate (MTX) during the remission-induction phase of psoriasis treatment.


In a 32-week, open-label, two-way cross-over study, patients (n = 20, seven men, aged 35–70 years) with moderate-to-severe plaque psoriasis were randomly assigned to receive MTX plus FA (20 mg/week) for 16 weeks followed by MTX monotherapy (three doses of MTX separated by 12-h intervals once a week) for an additional 16 weeks (treatment arm A, n = 10) or to receive the opposite sequence of treatments (arm B, n = 10). Dosing of MTX was individualised with the help of pre-study evaluation of plasma MTX pharmacokinetics. The Psoriasis Area and Severity Index (PASI), biochemistry and haematology tests and erythrocyte concentration of MTX polyglutamates (MTXPG) were evaluated throughout the study.


In arms A and B, the mean (range) concentrations of MTXPG (nmol/L) were comparable [week 16: 96.2 (32.0–157) vs. 111 (73.7–175), P = 0.32; week 32: 103 (55.8–173) vs. 83.6 (27.4–129), P = 0.24]. After 16 weeks, the mean±SEM PASI decreased from 20.1 ± 2.1 to 8.8 ± 1.3 in arm A, while a greater reduction from 27.2 ± 2.1 to 5.1 ± 1.0 occurred in arm B (P < 0.001). Positive correlations were found between the percent improvement in PASI at week 16 and the ratios of the concentration of MTXPG to plasma folate (rho = 0.59, P = 0.008) or RBC folate concentration (rho = 0.56, P = 0.013). Due to an accelerated decline in PASI in arm A and a trend to its worsening in arm B after crossing over of treatments, the mean absolute PASI scores in both arms were comparable at week 32.


The antipsoriatic effect of MTX during the remission-induction phase of treatment is influenced by folate status and may be significantly less if combined treatment with FA is used, irrespective of pre-treatment folate levels. The individual tailoring of MTX dosing needs further attention because the mean percent PASI improvement from baseline was 83% and the inter-patient variability in response was low after 16 weeks of monotherapy with MTX.


Methotrexate Folic acid Psoriasis Psoriasis Area and Severity Index 



The study was supported by grants from the Czech Ministry of Health no. NR7947-3/2004 and Czech Ministry of Education and Youth MSM 0021620820 and 1P05OC066.

Statement of competing interests

All authors (Jaroslav Chladek, Marie Simkova, Jaroslava Vaneckova, Milos Hroch, Jirina Chladkova, Jirina Martínková, Jaroslava Vávrová, Martin Beránek) declare that they have no competing interests.


  1. 1.
    Naldi L, Griffiths CE (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597–615PubMedCrossRefGoogle Scholar
  2. 2.
    Haustein UF, Rytter M (2000) Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. JEADV J Eur Acad Dermatol Venereol 14:382–388CrossRefGoogle Scholar
  3. 3.
    Grim J, Chladek J, Martinkova J (2003) J Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 42:139–151PubMedCrossRefGoogle Scholar
  4. 4.
    Chladek J, Grim J, Martinkova J et al (2002) Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 54:147–156PubMedCrossRefGoogle Scholar
  5. 5.
    van Ede AE, Laan RF, Blom HJ et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658–665CrossRefGoogle Scholar
  6. 6.
    Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH (2004) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 31:2374–2381PubMedGoogle Scholar
  7. 7.
    Morgan SL, Baggott JE, Lee JY, Alarcón GS (1998) Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 25:441–446PubMedGoogle Scholar
  8. 8.
    Whittle SL, Hughes RA (2004) Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43:267–271CrossRefGoogle Scholar
  9. 9.
    Strober BE, Menon K (2005) Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 53:652–659PubMedCrossRefGoogle Scholar
  10. 10.
    Salim A, Tan E, Ilchyshyn A, Berth-Jones J (2006) Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 154:1169–1174PubMedCrossRefGoogle Scholar
  11. 11.
    Boffa MJ (2005) Methotrexate for psoriasis: current European practice. A postal survey. JEADV J Eur Acad Dermatol Venereol 19:196–202CrossRefGoogle Scholar
  12. 12.
    Chladek J, Grim J, Martinkova J et al (2002) Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 54:147–156PubMedCrossRefGoogle Scholar
  13. 13.
    Dervieux T, Orentas Lein D, Marcelletti J et al (2003) HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 49:1632–1641PubMedCrossRefGoogle Scholar
  14. 14.
    Schroder H, Fogh K (1988) Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 21:145–149PubMedGoogle Scholar
  15. 15.
    Da Costa M, Iqbal MP (1981) The transport and accumulation of methotrexate in human erythrocytes. Cancer 48:2427–2432PubMedCrossRefGoogle Scholar
  16. 16.
    Chladek J, Grim J, Martinkova J et al (2005) Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol 96:247–248PubMedCrossRefGoogle Scholar
  17. 17.
    Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366–1377PubMedCrossRefGoogle Scholar
  18. 18.
    Kurnik D, Loebstein R, Fishbein E et al (2003) Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther 18:57–63PubMedCrossRefGoogle Scholar
  19. 19.
    Bressolle F, Kinowski JM, Morel J et al (2000) Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol 27:2110–2114PubMedGoogle Scholar
  20. 20.
    Lebbe C, Beyeler C, Gerber NJ, Reichen J (1994) Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 53:475–477PubMedCrossRefGoogle Scholar
  21. 21.
    Kremer JM, Petrillo GF, Hamilton RA (1995) Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 22:38–40PubMedGoogle Scholar
  22. 22.
    Chládek J, Martínková J, Šimková M et al (1998) Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of disease. Eur J Clin Pharmacol 53:437–444PubMedCrossRefGoogle Scholar
  23. 23.
    Strober BE, Siu K, Menon K (2006) Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 33:1442–1446PubMedGoogle Scholar
  24. 24.
    Heydendael VM, Spuls PI, Opmeer BC et al (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349:658–665PubMedCrossRefGoogle Scholar
  25. 25.
    Guinotte CL, Burns MG, Axume JA et al (2003) Methylenetetrahydrofolate reductase 677C->T variant modulates folate status response to controlled folate intakes in young women. J Nutr 133:1272–1280PubMedGoogle Scholar
  26. 26.
    Ede AE, Laan RF, Rood MJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524PubMedCrossRefGoogle Scholar
  27. 27.
    Morgan SL, Baggott JE, Vaughn WH et al (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 121:833–841PubMedGoogle Scholar
  28. 28.
    Saporito FC, Menter MA (2004) Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 50(2):301–309PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Jaroslav Chládek
    • 1
  • Marie Simková
    • 2
  • Jaroslava Vanecková
    • 2
  • Milos Hroch
    • 3
  • Jirina Chládkova
    • 4
  • Jirina Martínková
    • 5
  • Jaroslava Vávrová
    • 6
  • Martin Beránek
    • 6
  1. 1.Department of Pharmacology and Department of BiochemistryFaculty of Medicine, Charles UniversityHradec KraloveCzech Republic
  2. 2.Department of DermatologyUniversity HospitalHradec KraloveCzech Republic
  3. 3.Department of PharmacologyFaculty of Medicine, Charles UniversityHradec KraloveCzech Republic
  4. 4.Department of PaediatricsUniversity HospitalHradec KraloveCzech Republic
  5. 5.Department of Pharmacology, Faculty of MedicineCharles UniversityHradec KraloveCzech Republic
  6. 6.Department of Clinical Biochemistry and DiagnosticsUniversity HospitalHradec KraloveCzech Republic

Personalised recommendations